ClinicalTrials.gg
CompletedNCT03404466Updated Oct 30, 2020

To Explore the Safety and Efficacy of Hypidone Hydrochloride Tablets in Treatment of Patients With MDD

A Phase 1/2 interventional study of Hypidone Hydrochloride tablets in Major Depressive Disorder, sponsored by Zhejiang Huahai Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-10-30.

Sponsored by Zhejiang Huahai Pharmaceutical Co., Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Depressive Disorder, Major with a site in China — 74 open to participants now, 77 under way, 5 of them phase 3. Depressive Disorder, Major · China.

Enrollment
147th of 173
42 · median 120
Started
2018
with 9 others
Phase 1/2
2 of 206
none open now
Registered
46th of 206
by date

Among the 206 studies in Depressive Disorder, Major with a site in China, this one is the 147th largest by enrollment of the 173 interventional ones that give a count, is one of 10 that started in 2018, is one of 2 in phase 1/2, and was the 46th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

74 of the 206 studies in Depressive Disorder, Major with a site in China are open now. Recruiting first, the newest first:

69 more — sign in →

All 74 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Depressive Disorder, Major with a site in China, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the safety and efficacy of Hypidone Hydrochloride tablets in treatment of patients with major depressive disorder (MDD) by evaluating the change of MADRS total score from baseline to week 6.

Read the detailed description

A total of 40 major depressive disorder (MDD) subjects between the ages of 18-65 who have current major depressive disorder diagnosed by DSM-5 will be recruited, Subjects will be accepted into the protocol after an opportunity to review and provide voluntary written informed consent and completion of a comprehensive medical and psychiatric history, physical examination, mental status examination, and routine laboratory assessments The subjects will accept the drug treatment twice daily orally for 6 weeks, During the treatment follow up will occur at 8±1 days after treatment, 15±1 days after treatment, 29±2 days after treatment ,43±2 days after treatment to evaluate the safety and efficacy of the drug.

03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Outpatient, 18-65 years old, Male or female
  2. Current major depressive disorder diagnosed by ,single episode(296.21, 296.22, 296.23),or recurrent episode(296.31, 296.32, 296.33)
  3. Montgomery-Åsberg Depression Rating Scale (MADRS) total scores in both Screening and Baseline ≥ 26
  4. The first item of MADRS in both Screening and Baseline ≥ 3
  5. CGI-S in both Screening and Baseline ≥ 4
  6. Able to provide written

Exclusion criteria

Exclusion Criteria:

  1. Patients accord with other mental disorders diagnosed by
  2. Attempts to suicide, or who presently have a high risk of suicide, or The tenth item (Suicidal ideation) of C-SSRS ≥ 3
  3. Baseline total scores compared with the screening period, the reduction rate of MADRS ≥ 25%
  4. Subjects with serious or uncontrolled cardiovascular disease, liver disease, kidney disease, blood disease, endocrine disease, respiratory disease
  5. Subjects with abnormal(Male ≥ 450 msec, Female QTcF ≥ 470 msec )
  6. Treatment with a MAOI within the 2 weeks prior to the first dose of trial medication
  7. practicing 2 different treatment methods of antidepressants as recommended dose of full course
  8. Subjects who have had a Vagus Nerve Stimulation(VNS) device implanted or who have received Modified Electric Convulsive Therapy(MECT) or Transcranial Magnetic Stimulation (TMS) within 3 months of Screening, received light treatment, laser treatment, acupuncture and other Chinese medicine treatment, biofeedback treatment within 2 weeks of Screening
  9. Subjects with a history of true allergic response to more than 1 class of medications
  10. Subjects who participated in a clinical trial within the last 30 days.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    experimental group one

    10 mg of Hypidone Hydrochloride tablets

    Drug: Hypidone Hydrochloride tablets

  • Experimental
    experimental group two

    20 mg of Hypidone Hydrochloride tablets

    Drug: Hypidone Hydrochloride tablets

Interventions

  • DrugHypidone Hydrochloride tablets

    Hypidone Hydrochloride tablets 10 or 20mg/day Study drug is to be given orally, twice daily, for 6 weeks

06

What researchers measure

Primary outcomes

  1. Change in Montgomery-Asberg Depression Rating Scale (MADRS)

    Change from baseline in MADRS scores,the \*total\* score ranges\[0,60\],higher values represent a worse outcome

    Time frame: Screening,Baseline,8 day after treatment,15 day after treatment,29 day after treatment,43 day after treatment

Secondary outcomes

  1. Change in Hamilton Depression Scale 17 items(HAMD17)

    Change from baseline in HAMD17 scores,the \*total\* score ranges\[0,50\],higher values represent a worse outcome

    Time frame: Baseline,8 day after treatment,15 day after treatment,29 day after treatment,43 day after treatment

  2. Change in Hamilton Anxiety Rating Scale (HAM-A)

    Change from baseline in HAM-A scores,the \*total\* score ranges\[0,56\],higher values represent a worse outcome

    Time frame: Baseline, 8 day after treatment,15 day after treatment,29 day after treatment ,43 day after treatment

  3. Change in Clinical Global Impression of Severity Scale(CGI-S)

    Change from baseline in CGI-S scores,the \*total\* score ranges\[0,7\],higher values represent a worse outcome

    Time frame: Screening,Baseline, 8 day after treatment,15 day after treatment,29 day after treatment,43 day after treatment

  4. Change in Clinical Global Impression of Improvement Scale(CGI-I)

    the \*total\* score ranges\[0,7\],higher values represent a worse outcome

    Time frame: 8 day after treatment,15 day after treatment,29 day after treatment,43 day after treatment

  5. Columbia-Suicide Severity Rating Scale (C-SSRS)

    Safety index,no total score

    Time frame: Baseline,15 day after treatment,43 day after treatment

07

Study locations

1 site
  • Shanghai mental health center
    Shanghai, Shanghai 200030, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Jul 2018, 4 months.

Of 31 phase 1/2 interventional studies under Depressive Disorder, Major, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 75. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2018
First posted
Jan 19, 2018
StartActual
Feb 24, 2018
Primary completionActual
Jul 10, 2018
CompletionActual
Jul 17, 2018
Last update
Oct 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03404466
Lead sponsor
Zhejiang Huahai Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Jan 19, 2018
Start date
Feb 24, 2018
Primary completion
Jul 10, 2018
Completion
Jul 17, 2018
Last update
Oct 30, 2020

Study contacts

Huafang Li, PhD
principal investigator · Shanghai Mental Health Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion